• OxOnc Development LP, of Princeton, N.J., said it entered a co-development agreement with Pfizer Inc., of New York, to conduct a pivotal trial of Pfizer's Xalkori (crizotinib) in patients with non-small-cell lung cancer harboring a ROS1 (c-ros) gene rearrangement).